The role of adrenocorticotropin in the cortisol and aldosterone responses to angiotensin II in conscious dogs

Virginia Brooks, L. Daneshvar, I. A. Reid

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The role of ACTH in the cortisol and aldosterone responses to iv angiotensin II (AII) infusion (5, 10, and 20 ng kg-1 min-1) in dogs was evaluated by examining the effect of AII infusion in conscious dogs pretreated with dexamethasone to suppress endogenous ACTH secretion. AII infusion in untreated dogs produced dose-related increases in plasma cortisol and aldosterone concentrations. The plasma ACTH concentration also increased. Dexamethasone treatment lowered the basal cortisol concentration from 1.7 ± 0.1 to 0.7 ± 0.1 μg/dl (P <0.05) and the ACTH concentration from 52 ± 3 to 41 ± 4 pg/ml (P <0.05), and abolished the cortisol response to all doses of AII, indicating that ACTH was necessary for the response. On the other hand, the basal aldosterone concentration was not significantly affected by dexamethasone, although the aldosterone response to the highest dose of AII was reduced. Additional experiments were performed to determine if the cortisol and aldosterone responses to AII (20 ng kg-1 min-1) in dexamethasone-treated dogs are restored if the ACTH concentration is maintained near control levels by iv infusion of synthetic αACTH-(1-24) (0.3 ng kg-1 min-1). AII still failed to increase the plasma cortisol concentration in this group of dogs; however, the aldosterone response was fully restored. To evaluate the effect of elevated ACTH levels on the steroidogenic effects of AII, dogs were treated with dexamethasone and a higher dose of ACTH (0.4 ng kg-1 min-1). This dose of ACTH increased the plasma cortisol concentration from 1.7 ± 0.1 to 3.5 ± 0.8 μg/dl (P <0.05), but did not significantly affect the plasma aldosterone concentration. In the presence of constant elevated levels of ACTH, AII (10 and 20 ng kg-1 min-1) increased the plasma cortisol concentration in dexamethasone-treated dogs, although the response to the 10 ng kg-1 min-1 dose was smaller than the response in untreated dogs. Infusion of AII at 5 ng kg-1 min-1 did not increase the plasma cortisol concentration. In contrast, the increased plasma aldosterone produced by AII infusion in dexamethasone-treated dogs was not altered in the presence of elevated ACTH levels. Finally, AII infusion did not alter the clearance of cortisol. Collectively, these results demonstrate that an increase in plasma ACTH is necessary for the cortisol response to AII infusion. The elevated ACTH levels may increase cortisol production directly or may act to increase adrenal sensitivity to a direct action of AII. These results also suggest that a rise in ACTH does not contribute to the aldosterone response to AII, although ACTH may be needed for normal aldosterone responsiveness to high AII concentrations.

Original languageEnglish (US)
Pages (from-to)97-104
Number of pages8
JournalEndocrinology
Volume122
Issue number1
StatePublished - 1988
Externally publishedYes

Fingerprint

Aldosterone
Angiotensin II
Adrenocorticotropic Hormone
Hydrocortisone
Dogs
Dexamethasone
Cosyntropin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

The role of adrenocorticotropin in the cortisol and aldosterone responses to angiotensin II in conscious dogs. / Brooks, Virginia; Daneshvar, L.; Reid, I. A.

In: Endocrinology, Vol. 122, No. 1, 1988, p. 97-104.

Research output: Contribution to journalArticle

@article{b7a9c00035674217ab109eeff66643d8,
title = "The role of adrenocorticotropin in the cortisol and aldosterone responses to angiotensin II in conscious dogs",
abstract = "The role of ACTH in the cortisol and aldosterone responses to iv angiotensin II (AII) infusion (5, 10, and 20 ng kg-1 min-1) in dogs was evaluated by examining the effect of AII infusion in conscious dogs pretreated with dexamethasone to suppress endogenous ACTH secretion. AII infusion in untreated dogs produced dose-related increases in plasma cortisol and aldosterone concentrations. The plasma ACTH concentration also increased. Dexamethasone treatment lowered the basal cortisol concentration from 1.7 ± 0.1 to 0.7 ± 0.1 μg/dl (P <0.05) and the ACTH concentration from 52 ± 3 to 41 ± 4 pg/ml (P <0.05), and abolished the cortisol response to all doses of AII, indicating that ACTH was necessary for the response. On the other hand, the basal aldosterone concentration was not significantly affected by dexamethasone, although the aldosterone response to the highest dose of AII was reduced. Additional experiments were performed to determine if the cortisol and aldosterone responses to AII (20 ng kg-1 min-1) in dexamethasone-treated dogs are restored if the ACTH concentration is maintained near control levels by iv infusion of synthetic αACTH-(1-24) (0.3 ng kg-1 min-1). AII still failed to increase the plasma cortisol concentration in this group of dogs; however, the aldosterone response was fully restored. To evaluate the effect of elevated ACTH levels on the steroidogenic effects of AII, dogs were treated with dexamethasone and a higher dose of ACTH (0.4 ng kg-1 min-1). This dose of ACTH increased the plasma cortisol concentration from 1.7 ± 0.1 to 3.5 ± 0.8 μg/dl (P <0.05), but did not significantly affect the plasma aldosterone concentration. In the presence of constant elevated levels of ACTH, AII (10 and 20 ng kg-1 min-1) increased the plasma cortisol concentration in dexamethasone-treated dogs, although the response to the 10 ng kg-1 min-1 dose was smaller than the response in untreated dogs. Infusion of AII at 5 ng kg-1 min-1 did not increase the plasma cortisol concentration. In contrast, the increased plasma aldosterone produced by AII infusion in dexamethasone-treated dogs was not altered in the presence of elevated ACTH levels. Finally, AII infusion did not alter the clearance of cortisol. Collectively, these results demonstrate that an increase in plasma ACTH is necessary for the cortisol response to AII infusion. The elevated ACTH levels may increase cortisol production directly or may act to increase adrenal sensitivity to a direct action of AII. These results also suggest that a rise in ACTH does not contribute to the aldosterone response to AII, although ACTH may be needed for normal aldosterone responsiveness to high AII concentrations.",
author = "Virginia Brooks and L. Daneshvar and Reid, {I. A.}",
year = "1988",
language = "English (US)",
volume = "122",
pages = "97--104",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - The role of adrenocorticotropin in the cortisol and aldosterone responses to angiotensin II in conscious dogs

AU - Brooks, Virginia

AU - Daneshvar, L.

AU - Reid, I. A.

PY - 1988

Y1 - 1988

N2 - The role of ACTH in the cortisol and aldosterone responses to iv angiotensin II (AII) infusion (5, 10, and 20 ng kg-1 min-1) in dogs was evaluated by examining the effect of AII infusion in conscious dogs pretreated with dexamethasone to suppress endogenous ACTH secretion. AII infusion in untreated dogs produced dose-related increases in plasma cortisol and aldosterone concentrations. The plasma ACTH concentration also increased. Dexamethasone treatment lowered the basal cortisol concentration from 1.7 ± 0.1 to 0.7 ± 0.1 μg/dl (P <0.05) and the ACTH concentration from 52 ± 3 to 41 ± 4 pg/ml (P <0.05), and abolished the cortisol response to all doses of AII, indicating that ACTH was necessary for the response. On the other hand, the basal aldosterone concentration was not significantly affected by dexamethasone, although the aldosterone response to the highest dose of AII was reduced. Additional experiments were performed to determine if the cortisol and aldosterone responses to AII (20 ng kg-1 min-1) in dexamethasone-treated dogs are restored if the ACTH concentration is maintained near control levels by iv infusion of synthetic αACTH-(1-24) (0.3 ng kg-1 min-1). AII still failed to increase the plasma cortisol concentration in this group of dogs; however, the aldosterone response was fully restored. To evaluate the effect of elevated ACTH levels on the steroidogenic effects of AII, dogs were treated with dexamethasone and a higher dose of ACTH (0.4 ng kg-1 min-1). This dose of ACTH increased the plasma cortisol concentration from 1.7 ± 0.1 to 3.5 ± 0.8 μg/dl (P <0.05), but did not significantly affect the plasma aldosterone concentration. In the presence of constant elevated levels of ACTH, AII (10 and 20 ng kg-1 min-1) increased the plasma cortisol concentration in dexamethasone-treated dogs, although the response to the 10 ng kg-1 min-1 dose was smaller than the response in untreated dogs. Infusion of AII at 5 ng kg-1 min-1 did not increase the plasma cortisol concentration. In contrast, the increased plasma aldosterone produced by AII infusion in dexamethasone-treated dogs was not altered in the presence of elevated ACTH levels. Finally, AII infusion did not alter the clearance of cortisol. Collectively, these results demonstrate that an increase in plasma ACTH is necessary for the cortisol response to AII infusion. The elevated ACTH levels may increase cortisol production directly or may act to increase adrenal sensitivity to a direct action of AII. These results also suggest that a rise in ACTH does not contribute to the aldosterone response to AII, although ACTH may be needed for normal aldosterone responsiveness to high AII concentrations.

AB - The role of ACTH in the cortisol and aldosterone responses to iv angiotensin II (AII) infusion (5, 10, and 20 ng kg-1 min-1) in dogs was evaluated by examining the effect of AII infusion in conscious dogs pretreated with dexamethasone to suppress endogenous ACTH secretion. AII infusion in untreated dogs produced dose-related increases in plasma cortisol and aldosterone concentrations. The plasma ACTH concentration also increased. Dexamethasone treatment lowered the basal cortisol concentration from 1.7 ± 0.1 to 0.7 ± 0.1 μg/dl (P <0.05) and the ACTH concentration from 52 ± 3 to 41 ± 4 pg/ml (P <0.05), and abolished the cortisol response to all doses of AII, indicating that ACTH was necessary for the response. On the other hand, the basal aldosterone concentration was not significantly affected by dexamethasone, although the aldosterone response to the highest dose of AII was reduced. Additional experiments were performed to determine if the cortisol and aldosterone responses to AII (20 ng kg-1 min-1) in dexamethasone-treated dogs are restored if the ACTH concentration is maintained near control levels by iv infusion of synthetic αACTH-(1-24) (0.3 ng kg-1 min-1). AII still failed to increase the plasma cortisol concentration in this group of dogs; however, the aldosterone response was fully restored. To evaluate the effect of elevated ACTH levels on the steroidogenic effects of AII, dogs were treated with dexamethasone and a higher dose of ACTH (0.4 ng kg-1 min-1). This dose of ACTH increased the plasma cortisol concentration from 1.7 ± 0.1 to 3.5 ± 0.8 μg/dl (P <0.05), but did not significantly affect the plasma aldosterone concentration. In the presence of constant elevated levels of ACTH, AII (10 and 20 ng kg-1 min-1) increased the plasma cortisol concentration in dexamethasone-treated dogs, although the response to the 10 ng kg-1 min-1 dose was smaller than the response in untreated dogs. Infusion of AII at 5 ng kg-1 min-1 did not increase the plasma cortisol concentration. In contrast, the increased plasma aldosterone produced by AII infusion in dexamethasone-treated dogs was not altered in the presence of elevated ACTH levels. Finally, AII infusion did not alter the clearance of cortisol. Collectively, these results demonstrate that an increase in plasma ACTH is necessary for the cortisol response to AII infusion. The elevated ACTH levels may increase cortisol production directly or may act to increase adrenal sensitivity to a direct action of AII. These results also suggest that a rise in ACTH does not contribute to the aldosterone response to AII, although ACTH may be needed for normal aldosterone responsiveness to high AII concentrations.

UR - http://www.scopus.com/inward/record.url?scp=0023858367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023858367&partnerID=8YFLogxK

M3 - Article

VL - 122

SP - 97

EP - 104

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 1

ER -